Sweden · Delayed Price · Currency is SEK Biosergen AB Statistics
Total Valuation
Biosergen AB has a market cap or net worth of SEK 3.22 million. The enterprise value is -16,923.
| Market Cap | 3.22M |
| Enterprise Value | -16,923 |
Important Dates
The last earnings date was Tuesday, August 18, 2026.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosergen AB has 2.35 million shares outstanding. The number of shares has decreased by -26.03% in one year.
| Current Share Class | 2.35M |
| Shares Outstanding | 2.35M |
| Shares Change (YoY) | -26.03% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 42.01% |
| Float | 851,564 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.57 |
| P/TBV Ratio | 4.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07
| Current Ratio | 1.07 |
| Quick Ratio | 1.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,593.00 |
Financial Efficiency
Return on equity (ROE) is -194.21% and return on invested capital (ROIC) is -121.46%.
| Return on Equity (ROE) | -194.21% |
| Return on Assets (ROA) | -83.93% |
| Return on Invested Capital (ROIC) | -121.46% |
| Return on Capital Employed (ROCE) | -4,599.86% |
| Weighted Average Cost of Capital (WACC) | 3.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -32.32M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.16% in the last 52 weeks. The beta is -0.08, so Biosergen AB's price volatility has been lower than the market average.
| Beta (5Y) | -0.08 |
| 52-Week Price Change | -97.16% |
| 50-Day Moving Average | 4.59 |
| 200-Day Moving Average | 23.58 |
| Relative Strength Index (RSI) | 36.55 |
| Average Volume (20 Days) | 409,258 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.34M |
| Pretax Income | -32.32M |
| Net Income | -32.32M |
| EBITDA | n/a |
| EBIT | -32.34M |
| Earnings Per Share (EPS) | -13.77 |
Balance Sheet
The company has 3.23 million in cash and no debt, with a net cash position of 3.23 million or 1.38 per share.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | n/a |
| Net Cash | 3.23M |
| Net Cash Per Share | 1.38 |
| Equity (Book Value) | 704,000 |
| Book Value Per Share | 0.30 |
| Working Capital | 703,000 |
Cash Flow
| Operating Cash Flow | -31.46M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -30.18M |
| FCF Per Share | -12.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosergen AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 26.03% |
| Shareholder Yield | 26.03% |
| Earnings Yield | -1,004.51% |
| FCF Yield | -938.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 1, 2025. It was a reverse split with a ratio of 0.01.
| Last Split Date | Dec 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |